Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Pulmotect is raising $6,099,391.00 in new funding. Sources indicate as part of senior management President and Chief Operating Officer, Brenton Scott played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pulmotect

PULMOTECT, INC. is a bio-pharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases. Our technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague).

To learn more about Pulmotect, visit http://pulmotect.com/

Contact:
Brenton Scott, President and Chief Operating Officer
713-579-9226
bscott@pulmotect.com
https://www.linkedin.com/in/brenton-scott-762654b1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved